id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-343743-6k3soh1l	Chaudhary, Sachin	Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused	2020-09-09		.txt	text/plain	3348	169	41	Among the many excellent ongoing studies with good preclinical data in appropriate animal models, some arising directly from recent clinical observations, we were surprised to see studies proposing to use the FDA-approved anti-fibrotic therapies (nintedanib NCT04338802 and pirfenidone NCT04282902) for idiopathic pulmonary fibrosis (IPF) in COVID-19 patients. In this review, we posit that, unlike patients with IPF, the COVID-19 survivors will follow a familiar course of intense pulmonary inflammation, leading to mild scarring and near-normal lung function recovery over time. Fewer studies are available for outcomes in MERS, but similar to other causes of viral-induced lung injury, MERS survivors have a reduced quality of life (21) , and the pulmonary sequelae from MERS are mild. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge	./cache/cord-343743-6k3soh1l.txt	./txt/cord-343743-6k3soh1l.txt